Since p53-abnormal endometrial cancer shows an unfavourable prognosis and high disease-specific mortality, it is important to investigate efficient and relatively safe anticancer agents and to characterise novel molecular targets for cancer therapy. This evidence concerns the gene TP53 and cancer.